Publications by authors named "H Brummer-Korvenkontio"

Article Synopsis
  • - The study aimed to estimate the prevalence of chronic Hepatitis C Virus (cHCV) infections in EU/EEA countries for the year 2019, using a method called multi-parameter evidence synthesis (MPES) to analyze data from various sources.
  • - In 29 out of 30 EU/EEA countries, the overall cHCV prevalence was found to be 0.50%, with notably higher rates in the eastern EU/EEA (0.88%), and over a third of cases were linked to people who inject drugs (PWID).
  • - The findings indicate that while cHCV prevalence is generally low, targeted efforts are needed, particularly in eastern regions and among PWID, to
View Article and Find Full Text PDF

Aims: We measured the association between a history of incarceration and HIV positivity among people who inject drugs (PWID) across Europe.

Design, Setting And Participants: This was a cross-sectional, multi-site, multi-year propensity-score matched analysis conducted in Europe. Participants comprised community-recruited PWID who reported a recent injection (within the last 12 months).

View Article and Find Full Text PDF

Purpose: The Finnish HIV Quality of Care Register (FINHIV) was created to: (1) estimate the number of people living with HIV (PLWH) in Finland, (2) evaluate the national level of antiretroviral medication use and viral suppression, (3) examine the change in the HIV epidemic in Finland to pinpoint issues to address and (4) enable evaluation of the health of the PLWH by combining the FINHIV data with other national healthcare data.

Participants: The FINHIV includes all people diagnosed or being treated for HIV infection in Finland since 1984. The register was formed in 2020 by combining data from the National Infectious Diseases Register (information from time of diagnosis, data from 1984) and from the 21 HIV Clinics that treat HIV-positive patients in Finland (earliest data from 1998).

View Article and Find Full Text PDF

A robust estimate of the number of people with chronic hepatitis C virus (HCV) infection is essential for an appropriate public health response and for monitoring progress toward the WHO goal of eliminating viral hepatitis. Existing HCV prevalence studies in the European Union (EU)/European Economic Area (EEA) countries are heterogeneous and often of poor quality due to non-probability based sampling methods, small sample sizes and lack of standardization, leading to poor national representativeness. This project aimed to develop and pilot standardized protocols for undertaking nationally representative HCV prevalence surveys in the general adult population.

View Article and Find Full Text PDF

Background & Aims: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years.

Methods: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings.

View Article and Find Full Text PDF